Skip to content

Propofol during Minimal Invasive Surfactant Evaluation Study

Propofol during Minimal Invasive Surfactant Evaluation Study - PROMISES

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON40970
Enrollment
78
Registered
2014-12-08
Start date
2015-02-14
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome

Interventions

The administration of propofol (1 mg/kg) versus no sedation. In both groups standard comfort care will be given, which consists of administering sucrose 24% in the cheek pouch of the infant together

Sponsors

Neonatologie
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: Preterm infants (26-37 weeks of gestation) needing surfactant therapy for RDS according to local criteria (FiO2 > 30% and PEEP > 8).

Exclusion criteria

Exclusion criteria: Imminent need for intubation because of respiratory distress, apnea or persistent acidosis. Infants who suffer from pneumothorax or pulmonary hemorrhage.

Design outcomes

Primary

MeasureTime frame
The main study parameter is the comfort-neo score, the primary endpoint is the percentage of infants with a comfort-neo score below 14 during the procedure.

Secondary

MeasureTime frame
Secondary study parameters are; - Occurrence of positive pressure ventilation during and right after the procedure; - Occurrence of intubation needed during the procedure and within 24 hours; - Number of attempts of endotracheal insertion of angiocatheter; - Duration of the total procedure (from start inserting laryngoscope, until exit angiocatheter); - Complications occurring during the procedure: desaturation

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)